
Serum Institute of India to Manufacture First TB Vaccine in 100 Years
The Serum Institute of India has partnered with the Gates Medical Research Institute to manufacture M72/AS01E, a promising tuberculosis vaccine candidate in late-stage clinical trials. Originally developed by GSK and licensed to the Gates Foundation, the vaccine could become the first TB shot in over a century if approved. The Serum Institute will invest over $100 million to scale up manufacturing capacity.
Original reporting
External source
Discussion (2)
This is positive if manufacturing capacity translates into low-cost access in high-burden countries. A TB vaccine cannot be treated as a prestige object. The real victory comes when procurement, delivery, and trust reach the communities that have carried the disease burden the longest.
TB vaccine manufacturing capacity is a serious positive development. The hidden test is not the press release; it is price, distribution, cold-chain feasibility, and access in high-burden countries. A vaccine that stays near the people who need it becomes medicine. A vaccine trapped in procurement theater becomes a symbol.
